Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myeloid malignancies: mutations, models and management
Anne Murati, Mandy Brecqueville, Raynier Devillier, et al.
BMC Cancer (2012) Vol. 12, Iss. 1
Open Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

The spliceosome as a target of novel antitumour drugs
Sophie Bonnal, Luisa Vigevani, Juan Valcárcel
Nature Reviews Drug Discovery (2012) Vol. 11, Iss. 11, pp. 847-859
Closed Access | Times Cited: 399
JNK signalling in cancer: in need of new, smarter therapeutic targets
Concetta Bubici, Salvatore Papa
British Journal of Pharmacology (2013) Vol. 171, Iss. 1, pp. 24-37
Open Access | Times Cited: 323
The Long Noncoding RNA HOTAIR Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma Cells via downregualtion of p21WAF1/CIP1 Expression
Zhili Liu, Ming Sun, Kaihua Lu, et al.
PLoS ONE (2013) Vol. 8, Iss. 10, pp. e77293-e77293
Open Access | Times Cited: 296
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Garima Sharma, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Molecular Therapy (2020) Vol. 29, Iss. 2, pp. 571-586
Open Access | Times Cited: 204
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana, Saar Gill
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 183
CAR T-Cell Therapy in Hematological Malignancies
Theresa Haslauer, Richard Greil, Nadja Zaborsky, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8996-8996
Open Access | Times Cited: 132
Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation
Robert R. West, Amy P. Hsu, Steven M. Holland, et al.
Haematologica (2013) Vol. 99, Iss. 2, pp. 276-281
Open Access | Times Cited: 128
The Epigenetic Landscape of Acute Myeloid Leukemia
Emma Conway O’Brien, Steven M. Prideaux, Timothy Chevassut
Advances in Hematology (2014) Vol. 2014, pp. 1-15
Open Access | Times Cited: 97
Regulation of the Bone Marrow Niche by Inflammation
Ioannis Mitroulis, Lydia Kalafati, Martin Bornhäuser, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 88
Mutational landscape of AML with normal cytogenetics: Biological and clinical implications
Maria Paola Martelli, Paolo Sportoletti, Enrico Tiacci, et al.
Blood Reviews (2012) Vol. 27, Iss. 1, pp. 13-22
Closed Access | Times Cited: 97
HTLV-1 bZIP Factor HBZ Promotes Cell Proliferation and Genetic Instability by Activating OncomiRs
Céline Vernin, Morgan Thénoz, Christiane Pinatel, et al.
Cancer Research (2014) Vol. 74, Iss. 21, pp. 6082-6093
Open Access | Times Cited: 83
RETRACTED ARTICLE: Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells
Mengyao Sun, Jian‐Yong Zhu, Chunyan Zhang, et al.
Biotechnology Letters (2017) Vol. 39, Iss. 10, pp. 1477-1484
Open Access | Times Cited: 79
The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications
Ling Zhang, Kathy L. McGraw, David A. Sallman, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2016) Vol. 58, Iss. 8, pp. 1777-1790
Closed Access | Times Cited: 61
Inflammation as a driver of hematological malignancies
Sumedha Saluja, Ishu Bansal, Ruchi Bhardwaj, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Optimization of Antitumor Modulators of Pre-mRNA Splicing
Chandraiah Lagisetti, Gustavo Palacios, Tinopiwa Goronga, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 24, pp. 10033-10044
Open Access | Times Cited: 59
Integrated genome-scale analysis of the transcriptional regulatory landscape in a blood stem/progenitor cell model
Nicola K. Wilson, Stefan Schoenfelder, Rebecca Hannah, et al.
Blood (2016) Vol. 127, Iss. 13, pp. e12-e23
Open Access | Times Cited: 56
EZH2 in Myeloid Malignancies
Jenny Rinke, Andrew Chase, Nicholas C.P. Cross, et al.
Cells (2020) Vol. 9, Iss. 7, pp. 1639-1639
Open Access | Times Cited: 47
Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design
Almudena Aguilera-Diaz, Iria Vázquez, Beñat Ariceta, et al.
PLoS ONE (2020) Vol. 15, Iss. 1, pp. e0227986-e0227986
Open Access | Times Cited: 42
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia
Sabrina Opatz, Harald Polzer, Tobias Herold, et al.
Blood (2013) Vol. 122, Iss. 10, pp. 1761-1769
Open Access | Times Cited: 53
The biology and clinical impact of genetic lesions in myeloid malignancies
R. Coleman Lindsley, Benjamin L. Ebert
Blood (2013) Vol. 122, Iss. 23, pp. 3741-3748
Open Access | Times Cited: 50
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications
Paolo Sportoletti, Emanuela Varasano, Roberta Rossi, et al.
Leukemia (2014) Vol. 29, Iss. 2, pp. 269-278
Open Access | Times Cited: 44
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
Vibe Skov
Cancers (2020) Vol. 12, Iss. 8, pp. 2194-2194
Open Access | Times Cited: 35
Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms
Peiwen Zhang, Na You, Yiyi Ding, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Phase 1 study of Azacitidine in Combination with Quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN
Guillermo Montalban‐Bravo, Elias Jabbour, Kelly S. Chien, et al.
Leukemia Research (2024) Vol. 142, pp. 107518-107518
Closed Access | Times Cited: 4
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia
Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top